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Abstract
Lymphatic vessels are derived from venous endothelial cells and their formation is governed by the Vascular endothelial
growth factor C (VegfC)/Vegf receptor 3 (Vegfr3; Flt4) signaling pathway. Recent studies show that Collagen and Calcium
Binding EGF domains 1 protein (Ccbe1) enhances VegfC-dependent lymphangiogenesis. Both Ccbe1 and Flt4 have been
shown to be indispensable for lymphangiogenesis. However, how these essential players are transcriptionally regulated
remains poorly understood. In the case of angiogenesis, atypical E2fs (E2f7 and E2f8) however have been recently shown to
function as transcriptional activators for VegfA. Using a genome-wide approach we here identified both CCBE1 and FLT4 as
direct targets of atypical E2Fs. E2F7/8 directly bind and stimulate the CCBE1 promoter, while recruitment of E2F7/8 inhibits
the FLT4 promoter. Importantly, inactivation of e2f7/8 in zebrafish impaired venous sprouting and lymphangiogenesis with
reduced ccbe1 expression and increased flt4 expression. Remarkably, over-expression of e2f7/8 rescued Ccbe1- and Flt4-
dependent lymphangiogenesis phenotypes. Together these results identified E2f7/8 as novel in vivo transcriptional
regulators of Ccbe1 and Flt4, both essential genes for venous sprouting and lymphangiogenesis.
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Introduction
The lymphatic vascular system is a specialized capillary
network of blind ended vessels that are essential for maintaining
interstitial fluid balance, macro-molecular uptake and immune
cell trafficking. One of the main drivers behind lymphangiogen-
esis is the Vascular endothelial growth factor C (VegfC) – Vegf
Receptor 3 (Vegfr3; Flt4) pathway [1–4]. Tight regulation of
VegfC-Flt4 signaling is of fundamental importance for proper
lymphangiogenesis. It has been shown that Delta like ligand 4
(Dll4) suppresses VegfC-Flt4 signaling while Collagen- and
Calcium-binding EGF domains 1 (Ccbe1) enhances the biolog-
ical effect of VegfC, thereby regulating the lymphangiogenic
response in opposing ways [2,5]. Besides these important
findings, it currently remains unclear how these factors are
regulated at the transcriptional level.
The atypical E2fs, E2f7 and E2f8, form homo- or heterodimers,
possess two DNA binding domains and form thereby an unusual
duo within the E2F family [6–8]. E2f7/8 function predominantly
as transcriptional repressors of cell cycle genes involved in DNA
replication, DNA metabolism, DNA repair, mitosis and cytokinesis
[9,10]. However, we recently showed that E2f7/8 can also
function as a transcriptional activator of VegfA, thereby promot-
ing blood vessel formation [11]. The aim of this study was to
determine whether E2f7/8 modulate lymphangiogenesis through
transcriptional regulation of lymphangiogenic factors. We report
here that Flt4 and Ccbe1 are directly regulated by E2f7/8 and
thereby show that these atypical E2Fs are essential modulators of
lymphangiogenesis in vivo.
Results
E2F7/8 Directly Regulate CCBE1 and FLT4 Expression
Recently, we showed that E2f7/8 regulate VegfA dependent
angiogenesis in zebrafish [11]. To determine whether E2f7/8 also
control other angiogenenic or lymphangiogenic factors besides
VegfA, we searched in a recently published genome-wide
microarray analysis on E2f7/8-deficient E10.5 mouse fetuses
(Sox2-cre;E2f7loxP/2;E2f8loxP/2) [12] for de-regulated expression of
genes associated with the AmiGO gene ontology (GO) term
(lymph)angiogenesis (Figure 1A). This analysis revealed that
among the genes that have been shown to be indispensable for
lymphangiogenesis, only Ccbe1 and Flt4 were deregulated and
contained canonical E2f binding sequences within their proximal
promoter (Figure 1A, B) [2,13]. To investigate whether these genes
are indeed bound and regulated by E2F7/8, we first performed
chromatin immunoprecipitation (ChIP) experiments in HeLa cells
and found that both E2F7 and E2F8 bound strongly to the CCBE1
promoter (Figure 1C). E2F8 was also strongly enriched on the
FLT4 promoter, while E2F7 showed only weak binding
(Figure 1C), which might be due to the overall lower affinity of
the E2F7 antibody. We used a previously reported E2F binding
site within the E2F1 promoter and a non-specific site upstream as
controls (Figure 1C) [11]. Next we tested whether ectopic
expression of E2F7 was able to modulate the expression of CCBE1
and FLT4. To this extent we used HeLa cells which express E2F7-
eGFP upon administration of doxycycline [10]. Induction of E2F7
showed an increase in CCBE1 mRNA and a decrease in FLT4
mRNA and protein levels (Figure 1D). Additionally, phosphory-
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lation of extracellular-signal-regulated kinase (pERK), a down-
stream factor of FLT4 signaling, showed a decrease while total
ERK levels were unchanged (Figure 1D). As controls, two
previously described atypical E2F target genes, E2F1 and VEGFA,
were used (Figure 1D) [11]. Conformingly, knockdown (KD) of
E2F7 or E2F8 as well as the combination of E2F7/8 caused a
decrease in CCBE1 mRNA levels, while FLT4 mRNA and protein
levels were increased (Figure 1E, Figure S1A). Consistently,
downstream phosphorylation or ERK was increased upon deletion
of E2F7/8 (Figure 1E). The deregulation of CCBE1 and FLT4
was stronger by E2F7 KD and E2F7/8 KD compared to E2F8
KD, whereas E2F1 KD had no obvious effects (Figure S1A).
Consistent with previous reports, E2F7 KD resulted in derepres-
sion of E2F8 expression, and E2F8 KD lead to derepression of
E2F7 expression, indicating that atypical E2Fs can compensate for
each other [11] (Validation of the siRNA is shown in Figure S1A).
Next, we investigated whether E2F7/8 regulate CCBE1 and
FLT4 in cell types that reflect their in vivo expression pattern. As
ccbe1 is strongly expressed in mesenchymal cells in zebrafish (30
hpf) [13], we used mouse embryonic fibroblasts (MEFs). Flt4
expression in venous endothelial cells is essential to mediate the
budding of lymphatic precursors from the venous system [2]. In
addition, flt4 expression in lympathic endothelial cells (LECs) has
been shown to be important for LEC proliferation upon
stimulation with VEGFC in vitro [14]. Therefore, we used human
umbilical vein endothelial cord cells (HUVECs) and human
lymphatic endothelial cells (LECs) to investigate FLT4 expression.
Moreover, previous analysis on the spatio-temporal expression at
the onset of lymphangiogenesis, revealed a ubiquitous pattern for
atypical E2fs in mice (E9.5) and zebrafish (30 hours post
fertilization (hpf)) [6,11]. In line with these in vivo expression
patterns, we found in comparison to HeLa cells, a 4000 times
higher expression of Ccbe1 in MEFs and a 230 and 890 times
higher expression of FLT4 in HUVECs and LECs respectively. In
line with the reported expression of CCBE1 [5], CCBE1 mRNA
levels were nearly undetectable in LECs. In contrast, atypical E2Fs
displayed a comparable expression level in all three cell lines
(Figure S1B). Furthermore, we analyzed public available CHIP-
sequencing data (ENCODE; unavailable for LECs) for the
trimethylated Lys4 and Lys27 mark on histone H3, in which
Lys4 methylation positively regulates transcription while Lys27
methylation negatively regulates transcription [15,16]. Comparing
the levels of H3K4me3 and H3K27me3 between HUVECs, HeLa
cells and fibroblasts confirmed that the active transcription status
of E2F7, E2F8, CCBE1 and FLT4 promoters correlates with the
cell-type specific expression for CCBE1 in mesenchymal cells and
FLT4 in endothelial cells (Figure S1A). To test whether E2F7/8
are also capable of modulating CCBE1 and FLT4 expression in
MEFs, HUVECs and LECs, we inactivated E2F7/8 in these cell
lines utilizing a conditional deletion approach in E2f7loxP/loxP
E2f8loxP/loxP MEFs [6] and siRNA technology in endothelial cells.
As expected, knockdown of atypical E2fs in MEFs and HUVECs
resulted in decreased CCBE1 expression, while FLT4 showed an
increased expression in all three cell types (Figure S1B).
Together, our results show that E2F7/8 directly bind and
modulate CCBE1 and FLT4 expression in cell types that reflect
their in vivo expression pattern. The in vitro expression and
H3K4me3 and H3K27me3 CHIP-sequence data indicated that
E2F7/8 are ubiquitous expressed between all cell lines used, while
CCBE1 and FLT4 show a cell type specific expression pattern,
mesenchymal cells and endothelial cells respectively. Therefore,
we hypothesize that E2F7/8 do not provide an ON/OFF switch
for tissue specific expression pattern of CCBE1 and FLT4, but
rather fine-tune the expression levels of these lymphangiogenesis
factors.
Loss of e2f7/8 Impaired Venous Sprouting and
Lymphangiogenesis
To investigate E2f7/8 function in lymphangiogenesis in vivo, we
injected zebrafish embryos at the one-cell stage with full length
e2f7/8 mRNA or used morpholino oligomers (MOs) to prevent
correct splicing of e2f7/8. As described previously, sequencing of
MO induced miss-spliced e2f7 and e2f8 mRNA revealed the
presence of frameshifts or intron insertion upstream of DNA
binding domain [11]. Consistent with our in vitro studies,
knockdown (KD) of E2F7/8 resulted in decreased ccbe1 and
increased flt4 levels, while forced expression of e2f7/8 mRNA had
the opposite effect (Figure 2A, B). Furthermore, KD of e2f7/8 in a
transgenic line that drives YFP expression under the control of the
flt4 promoter showed 2-fold increased YFP expression, mainly
apparent in the ISVs (Figure 2C).
In zebrafish, lymphangiogenesis starts around 36 hpf [13,17]
with cells that sprout from the posterior cardinal vein (PCV). A
subset of these cells connects to the arterial intersegmental vessels
(aISVs) and remodels them to venous ISVs (vISVs), which
consequently determines the ratio of arteries and veins within
the trunk vasculature. The ‘‘non-connecting’’ cells migrate further
dorsally and populate the horizontal myoseptum (HM) and are
referred to as parachordal lymphangioblasts (PLs) [13]. Next, these
PLs start to migrate ventrally and dorsally from the HM
exclusively alongside aISVs [17] and give rise to the embryonic
lymphatic structures, including the thoracic duct (TD) [13].
We assessed E2f7/8 function during lymphangiogenesis by
using Tg(fli1a:gfp;flt1enh:rfp) zebrafish embryos, in which endothelial
cells (ECs) are labeled green and arterial ECs have an additional
red color [17]. At 52 hpf, KD of e2f7/8 resulted in a decreased
number of PLs at the HM (Figure 2D upper panel; 2E). As
described earlier, E2f7/8 morphants also display defects or missing
aISVs (Figure 2D upper panel) [11].
At 5 days post fertilization (dpf) we found a decreased number of
vISVs in e2f7/8 morphants (Figure 2F). Together with the reduced
number of PLs at the HM, these findings indicates that the total
number of cells initially sprouting from the PCV was reduced in
e2f7/8 morphants. Furthermore, the formation of the TD was
impaired in e2f7/8 morphants (Figure 2D lower panel; 2G). In
contrast, ectopic expression of e2f7/8 mRNA resulted in increased
number of both, PLs and vISVs, without any TD phenotype
(Figure 2D–G). Together these results suggest that e2f7/8 regulate
the number of cells emerging from the PCV during venous
sprouting.
Ectopic Expression of ccbe1 Partially Restored Venous
Sprouting in e2f7/8 Deficient Zebrafish
Given that Ccbe1 stimulates lymphangiogenesis and its
expression is regulated by atypical E2Fs, we reasoned that the
lymphatic phenotype in e2f7/8 morphants is a result of decreased
ccbe1 expression. To test this hypothesis, we co-injected ccbe1
mRNA in e2f7/8 morphants. Ectopic expression of ccbe1 alone
resulted in an increased numbers of PLs at the HM at 52 hpf
(Figure 2H and I). In addition, the increased number of PLs did
not affect the formation of the TD 5 dpf (Figure 2H–J). Co-
injecting ccbe1 mRNA in e2f7/8 morphants resulted in a partial
rescue of the number of PLs at 52 hpf, however, these PLs showed
an abnormal morphology (Figure 2H and I). To this extent, it
appeared that the majority of PLs connected to ISVs, however at
ectopic positions and without generating functional venous
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Figure 1. E2F7/8 directly regulate CCBE1 and FLT4 expression. A, Genes associated with the gene ontology (GO) term angiogenesis were
extracted from the Sox2-cre;E2f7loxP/2E2f8loxP/2 vs. wild-type E10.5 mouse embryos (P,0.05) database (GEO: GSE30488) and additionally analyzed for
E2F binding sites and their presence in GO lymphangiogenesis (GO:0001946). B, E2F binding elements within the CCBE1 and FLT4 promoter. Average
and canonical E2F binding consensus. C, E2F7 and E2F8 ChIP performed on CCBE1 and FLT4 promoters in HeLa cells, arrows in (B) indicate primers
used for ChIP. A previous reported E2F site within the E2F1 promoter and a non-specific site upstream (+700 bp) served as controls. D, mRNA and
protein levels of E2f7-EGFP inducible HeLa cells treated with doxycyclin (0.2 mg /ml) for 24 hours. E, mRNA and protein levels of HeLa cells treated
with scrambled or E2f7/8 siRNAs. Fold change in protein were calculated using TUBULIN as reference. Data presented as the average (6s.e.m.)
compared to the control condition in three independent experiments.
doi:10.1371/journal.pone.0073693.g001
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Figure 2. Loss of E2f7/8 impaired venous sprouting and lymphangiogenesis. A, In situ hybridisation and B, qPCR (** P,0.05; two
independent experiments with n= 10 per condition and experiment) for flt4 and ccbe1 in zebrafish embryos 32 hpf, un-injected control (nic) or
injected with e2f7/8 MOs or mRNA. C, Flt4:YFP transgene level of 36 hpf uninjected or e2f7/8 MOs injected embryos, lateral view (n = 30 per condition).
D–G Lateral images and quantification of Tg(fli1a:gfp;flt1enh:rfp) embryos treated as indicated and imaged at 52 hpf or 5 dpf. H–J Lateral images and
quantification of Tg(fli1a:gfp;flt1enh:rfp) embryos treated as indicated and imaged at 52 hpf or 5 dpf. Concentrations: e2f7/8 MOs (10 ng each); e2f7/8
mRNA (100 pg each); ccbe1 mRNA (100 pg). Open arrow heads indicate missing intersegmental vessels or dorsal longitudinal anastomotic vessel.
Closed arrow heads indicate PLs (upper panel) or the TD (lower panel). Arrows depict PLs that have connected to ISVs. Stars indicate missing TD
E2f7/8 Transcriptionaly Regulate Lymphangiogenesis
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connections (Figure 2H white arrows). The TD defects of e2f7/8
morphants were not rescued by ectopic expression of ccbe1,
possibly due to the early connection of the PLs to the ISVs
(Figure 2H and J). Furthermore, we show that ectopic overex-
pression of flt4 does not phenocopy the lymphangiogenesis defects
of e2f7/8 morphants (Figure S2A). Together, these findings suggest
that the lymphatic phenotype in e2f7/8 morphants is likely the
result of decreased expression of ccbe1.
Induction of E2f7/8 Restored Ccbe1-dependent Venous
Sprouting and Lymphangiogenesis
Considering that e2f7/8 mRNA induced ccbe1 expression
(Figure 2A,B), we hypothesized that e2f7/8 are able to rescue
the ccbe1 morphant phenotype, characterized by reduced venous
sprouting, which consequently leads to a decreased number of
veins, absence of PLs and loss of TD (Figure 3A–D) [13].
Consistent with the data that loss of E2F7/8 results in a decreased
expression of CCBE1, injection of e2f7/8 MOs together with ccbe1
MOs resulted in no apparent improvement of the ccbe1 MO
induced phenotype (Figure 3A–D). However, as hypothesized, co-
injecting e2f7/8 mRNA or ccbe1 mRNA in ccbe1 morphants
resulted in partial restoration of the number of PLs at the HM and
reappearance of TD fragments in 55% of the morphants
(Figure 3A,B,D). Although we could only rescue 55% of the
embryos co-injected with ccbe1 MO and e2f7/8mRNA on the level
of the TD, we found in almost all embryos a rescue in the number
of veins to the same extent as with ccbe1 mRNA, (Figure 3C).
These findings suggest that E2F7/8 promote venous sprouting and
lymphangiogenesis through transcriptional activation of ccbe1.
E2f7/8 Modulate Flt4-dependent Venous Sprouting,
Lymphangiogenesis, and arterial Hyperbranching
During venous sprouting, VegfC signaling specifically drives the
budding of (venous) ECs from the PCV, whereas ECs from the DA
and aISVs seem to be non-responsive to VegfC. Recently, it has
been shown that Dll4, which is expressed in the DA and aISVs,
maintains arterial ECs in a quiescent state during venous
sprouting. More specific, it was reported that Dll4 represses
VegfC-Flt4 signaling in arterial cells, without affecting flt4 and
vegfC mRNA levels and loss of Dll4 therefore resulted in
hyperbranching of aISVs (Figure 4A open arrowheads) [2]. We
used this hyperbranching phenotype during the onset of venous
sprouting in dll4 morphants to assess the transcriptional repression
of E2f7/8 on Flt4 signaling in vivo. In line with our finding that
e2f7/8 mRNA injections leads to decreased flt4 levels, we found
that ectopic expression of e2f7/8 mRNA partially suppressed the
hyperbranching phenotype in dll4 morphants (Figure 4A,B). Next,
we evaluated whether this suppression of hyperbranching by
E2f7/8 was specifically regulated through modulation of flt4
expression. First, we assessed if ectopically expressed flt4 was able
to induce a hyperbranching phenotype. At 52 hpf we sporadically
found hyperbranching of ISVs in flt4 mRNA injected embryos
(Figure S2A and B). We concluded that the suppression of Dll4 on
Flt4 signaling was robust enough to compensate for the increased
Flt4 signaling in flt4 mRNA injected embryos. To sensitize ISVs
for increased Flt4 signaling, we injected low amounts of dll4 (low)
morpholino and found a dramatic increase in hyperbranching
when flt4 mRNA was co-injected in dll4 (low) morphants (Figure
S2A and B). These findings provide strong evidence that Flt4
signaling promotes the hyperbranching phenotype in dll4
morphants. This increased hyperbranching phenotype in dll4
(low) MO, induced by flt4 mRNA, was suppressed by co-injecting
e2f7/8 mRNA. These studies suggest that ectopic expression of
e2f7/8 represses endogenous flt4 expression and thereby reduces
the total flt4 levels in flt4 mRNA and dll4 MO (low) injected
embryos, and consequently inhibits hyperbranching. Together,
these results indicate that Dll4 modulates Flt4 signaling in a
transcriptional independent manner [2], while E2f7/8 likely
regulate Flt4 signaling at the transcriptional level. Furthermore,
analysis of dll4 expression in e2f7/8 mRNA injected embryos by in
situ hybridization, showed a decrease in dll4 mRNA (data not
shown), excluding the possibility that E2f7/8-mediated suppres-
sion of the hyperbranching phenotype of dll4 morphants occurs
through upregulation of dll4 expression.
In addition to the hyperbranching phenotype, dll4 morphants
also displayed an almost complete absence of PLs and loss of TD
(Figure 4A,C,D,E) [2]. Moreover, ISVs of dll4 morphants have a
predominantly venous identity, suggesting that venous sprouting is
not completely lost, but that cells budding from the PCV are pre-
dominantly programmed to connect to aISVs rather than
migrating to the HM. To investigate if these phenotypes were
also due to loss of dll4 suppression on Flt4 signaling and whether
E2f7/8 are able to rescue these phenotypes by modulating flt4
expression, we first co-injected dll4 MO and e2f7/8 MOs. In line
with the results that KD of dll4 leads to the loss of repression of
VegfC-Flt4 signaling and loss of e2f7/8 would only lead to a
further increase of signaling by increased amounts of flt4, we found
no improvement of the phenotype in e2f7/8 and dll4 double-
morphants (Figure 4B–D). In contrast, ectopic expression of either
e2f7/8 mRNA or dll4 mRNA in dll4 morphants, increased the
number of PLs to almost wild-type levels. Moreover, the TD was
partially restored at 5 dpf. As ectopic expression of e2f7/8 also
consequently leads to increased expression of ccbe1, we checked
whether the rescue of the TD in dll4 morphants injected with e2f7/
8 mRNA was specifically due to repression of flt4 expression and
not due to increased ccbe1 expression. To this extent, we injected
ccbe1 mRNA in dll4 morphants and observed a minor increase in
PLs at 52 hpf whereas at 5 dpf the TD was absent (Figure S2C–F).
In addition, the morphology of the PLs in embryos injected with
ccbe1 mRNA and dll4 MO (Figure S2C; arrows) showed great
similarity with PLs in embryos injected with ccbe1 mRNA and
e2f7/8 MOs (Figure 2H; arrows). These results suggest that the
amount of Flt4 signaling might determine whether venous sprouts
contribute to the vascular system or will migrate further to the HM
and contribute to the lymphatic system. As mentioned above, the
vasculature of dll4 morphants consists out of almost 90% vISVs
(Figure 4A,D) and in line with our previous data, injection of e2f7/
8 mRNA or dll4 mRNA in dll4 morphants reduced the number of
veins (Figure 4D). However, injection of e2f7/8 MOs in dll4
morphants also significantly reduced the number of veins in dll4
morphants (Figure 4D). In regard with our previous data, loss of
E2f7/8 in dll4 morphants leads, next to the increased expression of
flt4, also to a decreased expression of ccbe1 (Figure 2A,B), resulting
in reduced venous sprouting and consequently to a lower number
of vISVs.
Together, these data provide strong evidence that E2f7/8 can
compensate for the loss of repression on Flt4 signaling in dll4
morphants by transcriptional repression of flt4, thereby leading to
the partial rescue of the hyperbranching phenotype, the arterial-
fragments. All scale bars are 100 mm. Data presented as the average (6s.e.m.) compared to the control condition in three independent experiments
(*** P,0.001). At least n = 150 embryos per condition in three independent experiments were used for D–J.
doi:10.1371/journal.pone.0073693.g002
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venous patterning defects and the impaired formation of PLs and
TD.
Discussion
In this study, we show that two important players of
lymphangiogenesis, Flt4 and Ccbe1, are directly regulated by
atypical E2Fs. We demonstrate that inactivation of E2f7/8 in
zebrafish impairs venous sprouting and lymphangiogenesis
accompanied by deregulated expression of ccbe1 and flt4.
Moreover, we show that E2f7/8 induction can rescue lymphan-
giogenesis defects caused by loss of Ccbe1 or by enhanced Flt4
signaling due to the loss of Dll4. From these findings we conclude,
that E2f7/8 are required for lymphangiogenesis through fine-
tuning Ccbe1 and Flt4 expression.
We recently showed that ablation of e2f7/8 in zebrafish resulted
in a vegfAa dependent angiogenesis phenotype [11]. However,
several studies indicated that venous sprouting and, thereby,
lymphangiogenesis is a VegfA independent process in zebrafish. It
was shown that VegfA dependent phosphorylation of Vegf
receptor 2 (KDR/Flk-1) acts mainly through downstream
signaling via the phospholipase C-c (PLC-c) - protein kinase C
(PKC) - Raf-mitogen activated protein (MAP) kinase pathway
[18,19]. Zebrafish mutant for PLC-c or injected with PLC-c
morpholino oligomers showed specific defects in the formation of
arteries, but not veins or parachordal lymphangioblasts [13,20].
These findings indicate that the lymphatic phenotype observed in
e2f7/8 deficient zebrafish is unlikely due to decreased vegfAa
expression.
Recently, it was shown that CCBE1 enhances the biological
effect of VEGFC on lymphangiogenesis [5,21]. This effect is most
likely mediated through VEGFR3 and raises the question why
E2F7/8 regulates CCBE1 and VEGFR3 in opposing ways. Our
expression data of the atypical E2Fs, CCBE1 and FLT4 in
different cell lines revealed that the atypical E2Fs are almost
equally expressed between these cell lines while CCBE1 (mesen-
chymal cells) and FLT4 (endothelial cells) show a cell type specific
expression pattern (Figure S1B). Moreover, this cell type specific
expression matches with the expression of E2F7/8, FLT4 and
CCBE1 in vivo ([2,5,6,13]. Furthermore, our experiments show
that the amount of Flt4 signaling, either modulated on the level of
expression or on the level of signaling output, in vivo is of crucial
importance for proper lymphangiogenesis in zebrafish embryos.
This observation suggests that genes involved in regulating Flt4
signaling need a precise and timely regulation. Our results suggest
that E2F7/8 do not function as a ON/OFF switch for expression
of ccbe1 and flt4. Instead, our findings support a model where
E2F7/8 fine-tune the expression levels of ccbe1 and flt4 in cell-type
specific manner and provide thereby a mechanism that ensures the
right amount of Flt4 signaling during lymphangiogenesis. In this
Figure 3. E2f7/8 rescued Ccbe1dependent lymphangiogenesis phenotype. A, Representative images of Tg(fli1a:gfp;flt1enh:rfp) un-injected
control embryos (nic) or embryos injected with e2f7/8 MOs or mRNA. B, C, D, Quantification of the indicated parameters. Concentrations: e2f7/8 MOs
(10 ng each); ccb1 MO (5 ng); e2f7/8 mRNA (100 pg each); ccbe1 mRNA (100 pg).Open arrow heads indicate in (A; upper panel) missing dorsal
longitudinal anastomotic vessels. Closed arrow heads indicate (upper panel in A) PLs or (lower panel, A) presence of the TD. All scale bars are 100 mm.
Stars indicate missing TD fragments. Data presented as the average (6s.e.m.) compared to the control condition in three independent experiments
(*** P,0.001). At least n = 150 embryos per condition in three independent experiments were used for A–D.
doi:10.1371/journal.pone.0073693.g003
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model, the transcriptional effect of the atypical E2Fs on the
promoter of their target genes depends on their interaction with
co-factors and, moreover, is cell type specific. To this extent,
several reports show that E2Fs recruit co-factors that determines
their transcriptional potency [22–24]. Recently, we showed that
E2F7 needs to cooperate with HIF1 to induce VEGFA
transcription [11]. In this specific case, HIF1 not only determines
the transcriptional activity of E2F7, but also provides an additional
way to interact with the DNA through HIF binding sites. Thus, we
suggest that the contrasting modulation of Ccbe1 and Flt4 by
E2f7/8 might be achieved by the recruitment of additional factors,
which display a tissue specific expression. The overlap in
expression for hif1a [25], ccbe1 [13] and e2f7/8 [11] in zebrafish
embryos might be Illustrative for this hypothesis.
The dual role of atypical E2Fs in regulating cell cycle and
lymphangiogenesis is particularly interesting in the context of
cancer. Atypical E2Fs are highly expressed in many types of
tumors (Oncomine). Furthermore, dissemination of tumor cells
often occurs via the lymphatic system and can be blocked by
interfering with FLT4 signaling [26,27]. Thus, it would be of great
interest to investigate whether E2F7/8 not only control CCBE1
and FLT4 during developmental lymphangiogenesis but also
during tumor dissemination.
Our previous finding that e2f7/8 regulate angiogenesis [11],
provided strong evidence that atypical E2fs possess functions that
reach beyond cell cycle control. In support, we show here that
E2f7/8 regulate Ccbe1 and Flt4, two indispensable genes for
lymphangiogenesis in vivo.
Methods
Ethics Statements
Animal experiments were performed in accordance with the
rules of the Animal Experimentation Committee of the Royal
Netherlands Academy of Arts and Sciences (DEC).
Zebrafish
All zebrafish strains were maintained in the Hubrecht Institute
(Utrecht Medical Center, Netherlands) under standard husbandry
conditions. Transgenic lines used Tg(fli1a:gfp)y1 [28], Tg(flt1enh:rfp)
[17]. The transgenic reporter line Tg(flt4:YFP) was generated from
BAC DKEY-58G10 using standard methods [17] and will be
described in detail elsewhere.
Quantification
Parachordal lymphangioblasts [13,17] and thoracic duct were
quantified in zebrafish embryos as follows: the space between two
Figure 4. E2f7/8 rescued Flt4-dependent lymphangiogenesis phenotypes. A, Representative images of Tg(fli1a:gfp;flt1enh:rfp) un-injected
control embryos (nic) or embryos injected with e2f7/8MOs or mRNA. B, C, D, E Quantification of the indicated parameters. Concentrations: e2f7/8MOs
(10 ng each); dll4 MO (3 ng); e2f7/8 mRNA (100 pg each); dll4 mRNA (100 pg).Open arrow heads indicate in (A; upper panel) hyper-branching of
intersegmental vessels. Closed arrow heads indicate (upper panel in A) PLs or (lower panel, A) presence of the TD. All scale bars are 100 mm. Stars
indicate missing TD fragments. Data presented as the average (6s.e.m.) compared to the control condition in three independent experiments (***
P,0.001). At least n = 150 embryos per condition in three independent experiments were used for A–E.
doi:10.1371/journal.pone.0073693.g004
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intersegmental vessels was considered as 1 segment. 10 segments
anterior from the end of the yolk sac extension were quantified at
the indicated time points.
Micro-array Analysis
Data from Gene Expression Omnibus (GEO) database number
GSE30488 was analyzed by FlexArray [29]. All significant genes
associated with AmiGO gene ontology lists, angiogenesis
(GO:0001525) were extracted and analyzed for E2F binding
elements within their proximal promoters with DAVID (http://
david.abcc.ncifcrf.gov/[30,31]). Additionally, genes with E2F
binding elements that showed a deregulation (up or down) were
further analyzed for their association with GO term lymphangio-
genesis (GO:0001946). GO terms were retrieved from (http://
www.geneontology.org/[32]). Promoter analysis was performed
with Consite (http://asp.ii.uib.no:8090/cgi-bin/CONSITE/
consite/).
Morpholino
The following morpholino oligonucleotides (Genetools) were
used. E2f7 splice morpholino targeting exon 2–intron 2–3: 59-
ATAAAGTACGATTATCCAAATGCAC-39 [11]; e2f8 splice
morpholino targeting exon 2-intron 2–3: 59-CTCACAGG-
TATCCGAAAAAGTCATT-39 [11]; dll4 splice morpholino
targeting exon 4– intron 4–5: 59- TGATCTCTGATTGCT-
TACGTTCTTC-39 [2]; ccbe1 ATG morpholino: 59- CGGGTA-
GATCATTTCAGACACTCTG-39 [13]. Concentration of mor-
pholinos used are noted in the figure legends.
Imaging
Embryos were mounted in 0.5–1% low melting point agarose
(Invtrogen) dissolved in E3 buffer (5 mM NaCl, 0.17 mM KCl,
0.33 mM CaCl2, 0.33 mM MgSO4) on a culture dish with a glass
cover slip replacing the bottom. Imaging was performed with a
Leica SP2 confocal microscope (Leica Microsystems) using a 106
or 206 objective with digital zoom.
Quantification flt4:YFP Reporter Line
For all experiments the same male and female flt4:YFP fish were
crossed and offsprings were either injected with e2f7/8 MO or
uninjected. For each condition 30 embryos were imaged by
confocal microscopy with the same settings in three independent
experiments. Images were processed with image J. First the image
was converted to a binary image. Second, all black pixels were
quantified by imageJ and used for statistical analysis (Mann–
Whitney U-test).
Plasmid Constructs
E2f7 [11] and e2f8 [11] pCS2+ plasmids were linearized with
NotI and mRNA was synthesized using the SP6 RNA polymerase
and the mMachine kit (Ambion).
In situ Hybridization
In situ hybridization was performed as previously described
[33]. The ccbe1 [13] and flt4 [34] probes have been described
previously. Probes were synthesized by in vitro transcription using
T7 RNA polymerase (Promega).
Cell Culture, Overexpression and siRNA Transfection
Cervical cancer (HeLa) cell lines were cultured in DMEM
(Invitrogen, 41966-052) supplemented with 10% FBS (Lonza,
DE14-802F). Lymphatic endothelial cells (LECs) were cultured in
supplemented EGM-2 medium (Lonnza). Cells were transfected as
specified by the manufacturer using 5 ml/p60 dish (Greiner)
Lipofectamine 2000 (Invitrogen) with the following concentrations
of siRNA: single transfections had a final concentration of 25 nM
siRNA, double transfection had a final concentration of 50 nM
siRNAs (2625 nM). In case of single transfection the Scrambled
siRNA concentration was 25 nM, while in case of double
transfection the concentration of the Scrambled siRNA was
50 nM. Cell were grown for 24 hours. Alternatively, overexpres-
sion was induced by adding 0.2 mg ml21 doxycycline (Sigma) to
the cell culture medium, treatment duration was 12 hours. After
incubation of siRNAs or doxycycline with the indicated duration,
cells were washed with PBS and trypsinized (lonza; cc-5012),
pelleted by centrifugation (26006g, 29, 4uC), snap freezed in liquid
nitrogen and stored in 280uC for RNA or protein isolation.
Protein was isolated by disrupting cells in lysis buffer (0.05 M
sodium phosphate pH 7.3, 0.3 M NaCl, 0.1% NP40, 10%
Glycerol) supplemented with protease inhibitors (Roche). Total
RNA was extracted according to manufacturers’ instructions using
the RNeasy Mini Kit (Qiagen, cat #74106).
RNAi used in this study: scrambled siRNA #2 (D-001210-02,
Thermo Scientific). hE2F7 (HSS175354, Invitrogen), hE2F8
(HSS128760, Invitrogen).
SDS-PAGE, Western Blot and Protein Quantification
Cells were harvested (as described under siRNA transfection).
Cell lysates were subjected to standard ECL reagents as described
by the manufacturer (GE Healthcare, RPN2106). Used antibodies:
E2F1 (Santa Cruz Biotechnology, sc-193) E2F7 (Santa Cruz
Biotechnology, sc-66870), E2F8 (Abcam, AB109596), FLT4
(Santa Cruz Biotechnology; sc-321), ERK (Santa Cruz Biotech-
nology; sc-94), pERK (Santa Cruz Biotechnology; sc-7383), Mouse
IgG HRP-linked whole Ab (GE Healthcare, NA931), Rabbit IgG
HRP-linked whole Ab (GE Healthcare, NA934).
Relative protein levels were determined with gel analyzer in
ImageJ (http://rsbweb.nih.gov/ij/). Protein loading was equalized
with TUBULIN and fold changes were calculated.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed according the EZ ChIP protocol (Upstate,
17–371) using protein G agarose beads (Milipore, 16–266) coated
overnight in 0,1% BSA (Sigma, A3294). The following antibodies
were used: E2F7 (Santa Cruz Biotechnology; sc-66870) and E2F8
(Abcam, AB109596). De-crosslinked DNA was purified over a
column (Qiagen, 28106) and eluted in 50 ml H2O of which 2 ml
was used for quantitative PCR.
RNA Isolation, cDNA Synthesis and Quantitative PCR
cDNA was synthesized with random hexamer primers accord-
ing to manufacturers’ instructions (Fermentas, cat#K1622).
Quantitative PCR was performed on a MyiQ cycler (Biorad)
using SYBRgreen chemistry (Biorad). In our in vitro studies two
reference genes were used (ACTB, RPS18) and for zebrafish
samples three reference genes were used (TBP, EF1a, b Actin).
MIQE standards were applied to our protocols [35]. The
sequences of all primers used in this manuscript are shown in
Table 1.
Statistical Analysis
For statistical analysis of two groups, unpaired t-test, or in case
of unequal variances, Mann–Whitney U-test were used. For
statistical analysis of multiple groups, one-way ANOVA, or in case
of unequal variances, Kruskal–Wallis test was used. Dunns post hoc
test were used to compare between selected groups. P-values,0.05
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were considered significant. Statistical analysis was performed
using SPSS 20 (IBM).
Supporting Information
Figure S1 E2F7/8 directly regulate CCBE1 and FLT4
expression. S1A, protein and mRNA expression of indicated
genes in HeLa cells treated with Scrambled, E2F1, E2F7, E2F8 or
E2F7/8 siRNAs. S2B, Relative expression of indicated gene in
HeLa, HUVECs, MEFs and LECs. Additional, in silico analysis of
the trimethylated Lys4 and Lys27 mark on histone H3 in HeLa,
HUVECs and normal human lung fibroblasts (NHLF). S1C,
indicated mRNA levels in Cre inducible E2f7loxP/loxPE2f8loxP/loxP
MEFs treated with tamoxifen (0.2 mg /ml) for 24 hours and
E2F7/8 siRNA treated HUVECs and LECs. Data presented as
the average (6s.e.m.) compared to the control condition in two
independent experiments.
(TIF)
Figure S2 Hyperbranching and venous sprouting is
dependent on proper Flt4 signaling. S2A Lateral images
and quantification of Tg(fli1a:gfp;flt1enh:rfp) embryos treated as
indicated and imaged at 52 hpf. S2C Lateral images and
quantification of Tg(fli1a:gfp;flt1enh:rfp) embryos treated as indicated
and imaged at 52 hpf. S2D, S2E, S2F, quantification of the
indicated parameters. Concentrations: dll4 MO (low 1.5 ng in S2A
and 3 ng in S2C–F); e2f7/8 mRNA (100 pg each); flt4 mRNA
(100 pg); ccbe1 mRNA (100 pg). Arrows depict PLs that have
connected to ISVs (S2C). Closed arrow heads indicate (upper
panel in S2C) PLs or (lower panel, S2C) presence of the TD. Open
arrowheads indicate hyperbranching ISVs. All scale bars are
100 mm. Stars indicate missing TD fragments. Data presented as
the average (6s.e.m.) compared to the control condition in three
independent experiments (*** P,0.001). At least n = 150 embryos
per condition in three independent experiments were used for
S2A–S2F.
(TIF)
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